News

MedPage Today4m
FDA Approves Twice-Yearly Shot for HIV Prevention
The FDA approved lenacapavir (Yeztugo) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at ...
Agence France-Presse on MSN20m
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move ...
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
FDA approves new twice-yearly HIV shot. What to know
Gilead said the price is comparable to existing HIV prevention drugs and the company will work with insurers to obtain broad coverage of the drug. Advocates say the long-acting medication ...
FDA approves 6-month HIV prevention shot
Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more ...
Long-acting HIV prevention drug from Gilead wins FDA approval. Will it get to the people who need it?
Jared Baeten is Gilead Sciences Inc.'s senior vice president of clinical development and head of the virology therapeutic ...